Tag: large-cap

Abbott Laboratories (ABT) is rated Hold as its diversified healthcare platform supports stability, but valuation and execution concerns cap near-term upside. Q1 2026 revenue and EBIT weakened sequentially, while debt tied to acquisition financing could pressure flexibility.

Read note